In a nutshell This study evaluated the long-term outcomes of patients with ALK-positive non-small-cell lung cancer (NSCLC) treated with alectinib (Alecensa). This study concluded that this treatment improved survival without cancer worsening in these patients. Some background ALK-positive non-small-cell lung cancer (NSCLC) remains a difficult to treat...
Read MoreIn a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...
Read More
In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies. They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...
Read More
In a nutshell This study wanted to find out if the medication brigatinib (Alunbrig) is better than crizotinib (Xalkori) in treating patients with lung cancer. The study found that survival was significantly longer in patients who were treated with brigatinib compared to those treated with crizotinib. Some background Brigatinib and crizotinib are a...
Read More
In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of ceritinib (Zykadia) treatment, in treating ALK positive non-small cell lung cancer (NSCLC) with brain metastases and/or leptomeningeal carcinomatosis. The primary outcome will be measured by the disease response to treatment. The details Some lung cancers are associated...
Read More
In a nutshell The American Society of Clinical Oncology (ASCO) gathered a panel of experts to update guidelines on systemic therapy (such as chemotherapy) for stage 4 non-small cell lung cancer (NSCLC). They provided updated guidelines with recommendations for first, second and third-line systemic therapy as well as targeted therapy. Some...
Read More
In a nutshell This study looked at whether crizotinib and then ceritinib helped improve survival rates in patients with lung cancer. Some background Anaplastic lymphoma kinase (ALK) is an important protein involved in cell development. It is estimated that genetic changes that alter the function of ALK are found in 3-5% of all non-small cell lung...
Read More
In a nutshell The authors aimed to analyze the safety and effectiveness of crizotinib (Xalkori) in Chinese patients with advanced non-small cell lung cancer (NSCLC). Some background NSCLC is the most common type of lung cancer. In some patients with NSCLC, a gene called ALK is turned on (ALK positive) which leads to incorrect interaction of ALK...
Read More
In a nutshell This article evaluated best treatment options for wild-type epidermal growth factor receptor (EGFR) lung cancer. Specifically, it compared outcomes using EGFR-targeted drugs versus conventional chemotherapy. Some background The EGFR gene is responsible for building a specific protein needed by cancer cells to multiply. Mutations...
Read More
In a nutshell This phase III trial investigated the benefits of crizotinib (Xalkori) as treatment for ALK-positive lung cancer patients. Patient outcome with crizotinib treatment was compared to that of treatment with standard chemotherapy. Some background Non-small-cell lung cancer (NSCLC) cells may contain different...
Read More
